Work

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-125363

Authors: Amer M. Zeidan, Daniel J. DeAngelo, Jeanne M. Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei, Ying Fei Li, Nanette Hock, Michael R. Burgess, Kristen Hege, Wendy Stock

Institutions: Yale Cancer Center, Yale University, Dana-Farber Cancer Institute, Mayo Clinic Hospital, University of California, Los Angeles, Memorial Sloan Kettering Cancer Center, Celgene (United States), University of Chicago

Language: English

Topic: Phagocytosis and Immune Regulation

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2988420853

Cites:

Cited by: 52

Related to: 10